ASP Isotopes Inc. Common Stock(ASPI)Earnings, Financials & Key RatiosASP Isotopes Inc. Common Stock (ASPI) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on debt-financed growth and the persistent disconnect between net income and operating cash flow, evidenced by an OCF/NI ratio of 2.58 in 2026Q1, suggest that the firm is not yet ready for sustainable commercial operations.
ASP Isotopes Inc. Common Stock (ASPI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
ASP Isotopes Inc. Common Stock (ASPI) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 20, 2026 | $0.22vs $0.06-266.7% | $4Mvs $4M-5.6% |
| Q2 2026 | Apr 10, 2026 | $0.84vs $0.10-740.0% | $17Mvs $2M+721.3% |
| Q4 2025 | Nov 19, 2025 | $0.15vs $0.15+0.0% | $5Mvs $2M+140.8% |
| Q3 2025 | Aug 14, 2025 | $1.03vs $1.03+0.0% | $1Mvs $2M-25.1% |
Recent stock market news and headlines for ASP Isotopes Inc. Common Stock (ASPI)
ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," âASPIâ or the "Company"), an advanced materials company focused on developing technologies and processes
DALLAS & ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #MASLD--ASP Isotopes Inc. (NASDAQ: ASPI) ("ASP Isotopes," “ASPI” or the "Company"), an advanced materials company focused on developing technologies and processes for the production of critical materials used in multiple industries, and ENDRA Life Sciences Inc. (NASDAQ: NDRA) (“ENDRA” or “NDRA”), a pioneer in thermoacoustic biomarker imaging for early detection and monitoring of steatotic liver disease (SLD), today announced that ASP Isotopes' wholly-owned su.
Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen's Virginia Gas Project
Combination, if successful, would establish Noble Africa as a Nasdaq-listed, helium platform for Renergen's Virginia Gas Project Listing expected to provide investors with direct exposure to one of the few publicly traded helium development assets globally, at a time of tightening supply Concurrent private placement expected to generate approximately $50 million in gross proceeds to support project development DALLAS and ANN ARBOR, Mich.
Key metrics vs top competitors for ASP Isotopes Inc. Common Stock (ASPI)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.53 | $459.53M | -2.62 | 475.51% | -734.17% | -111.5% | — | |
| $8.86 | $84.1M | 4922.22 | -0.97% | -0.87% | -1.01% | — | |
| $174.23 | $3.3B | 44.67 | 1.52% | 13.4% | 10.71% | — | |
| $10.57 | $5.23B | -52.85 | 29737.95% | -516.16% | -8.13% | — | |
| $20.19 | $839.55M | -19.05 | — | — | -7.62% | — | |
| $13.77 | $3.44B | -37.22 | -15.61% | -82.7% | -10.16% | — |
ASP Isotopes Inc. Common Stock (ASPI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASP Isotopes Inc. Common Stock (ASPI) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 26, 2026·SEC
May 20, 2026·SEC
May 11, 2026·SEC
Apr 10, 2026·SEC
Get notified when ASPI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ASP Isotopes Inc. Common Stock (ASPI) stock FAQ — growth, dividends, profitability & financials explained
ASP Isotopes Inc. Common Stock (ASPI) reported $26.9M in revenue for fiscal year 2025.
ASP Isotopes Inc. Common Stock (ASPI) grew revenue by 475.5% over the past year. This is strong growth.
ASP Isotopes Inc. Common Stock (ASPI) reported a net loss of $173.5M for fiscal year 2025.
ASP Isotopes Inc. Common Stock (ASPI) has a return on equity (ROE) of -111.5%. Negative ROE indicates the company is unprofitable.
ASP Isotopes Inc. Common Stock (ASPI) had negative free cash flow of $65.8M in fiscal year 2025, likely due to heavy capital investments.
